Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last CNY13.13 CNY
Change Today +0.79 / 6.40%
Volume 41.1M
As of 3:05 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

zhejiang conba pharmaceuti-a (600572) Snapshot

Open
CNY12.65
Previous Close
CNY12.34
Day High
CNY13.30
Day Low
CNY12.35
52 Week High
06/9/15 - CNY19.78
52 Week Low
12/31/14 - CNY8.66
Market Cap
22.0B
Average Volume 10 Days
43.1M
EPS TTM
CNY0.49
Shares Outstanding
1.7B
EX-Date
07/7/15
P/E TM
26.8x
Dividend
CNY0.10
Dividend Yield
0.76%
Current Stock Chart for ZHEJIANG CONBA PHARMACEUTI-A (600572)

Related News

No related news articles were found.

zhejiang conba pharmaceuti-a (600572) Related Businessweek News

No Related Businessweek News Found

zhejiang conba pharmaceuti-a (600572) Details

Zhejiang Conba Pharmaceutical Co., Ltd. operates as a pharmaceutical company in the People’s Republic of China. It provides traditional Chinese medicines, botanical extracts, chemical medicines, chemical raw medicines, health foods, common foods, prepared drugs in pieces, and commodities. The company offers its products under the Conba, Prostate Plus, Zhenshiming, Prostate Plus, Tianbaoning, Alocin, Xitao, Yuanbang, Baby, Omeprazole, etc. brands. The company was formerly known as Lanxi Yunshan Pharmaceutical Factory and changed its name to Zhejiang Conba Pharmaceutical Co., Ltd. in October 1999. Zhejiang Conba Pharmaceutical Co., Ltd. was founded in 1969 and is headquartered in Hangzhou, the People’s Republic of China.

Founded in 1969

zhejiang conba pharmaceuti-a (600572) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

zhejiang conba pharmaceuti-a (600572) Key Developments

Zhejiang Conba Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Half of 2015

Zhejiang Conba Pharmaceutical Co.,Ltd. reported earnings results for the first Half of 2015. For the period, basic earnings per share was CNY 0.51. Weighted average return on net assets was 12.68%.

Zhejiang Conba Pharmaceutical Co.,Ltd. to Report First Half, 2015 Results on Aug 25, 2015

Zhejiang Conba Pharmaceutical Co.,Ltd. announced that they will report first half, 2015 results on Aug 25, 2015

Zhejiang Conba Pharmaceutical Co.,Ltd. expected to report Q2 2015 results on August 15, 2015. This event was calculated by Capital IQ (Created on August 9, 2015).

Zhejiang Conba Pharmaceutical Co.,Ltd. expected to report Q2 2015 results on August 15, 2015. This event was calculated by Capital IQ (Created on August 9, 2015).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
600572:CH CNY13.13 CNY +0.79

600572 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 600572.
View Industry Companies
 

Industry Analysis

600572

Industry Average

Valuation 600572 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow 28.4x
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZHEJIANG CONBA PHARMACEUTI-A, please visit www.conba.com.cn. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.